# Senhwa Biosciences Launches Global Study, Targeting Breakthrough in Hard-to-Treat Cancers with CX-5461 and Tislelizumab Combination

- Link: https://www.thailand-business-news.com/pr-news/senhwa-biosciences-launches-global-study-targeting-breakthrough-in-hard-to-treat-cancers-with-cx-5461-and-tislelizumab-combination
- Published: 2026-05-05T14:40:00+07:00
- Author: PR Newswire

|   |

TAIPEI and SAN DIEGO, May 5, 2026 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx:
6492), a clinical-stage biopharmaceutical company today announced the initiation
of a global, multi-center clinical trial. The Company has also submitted an Investigational
New Drug (IND) application to the U.S. Food and Drug Administration (FDA), marking
a key milestone in Senhwa’s global clinical development.

The study will evaluate Senhwa’s first-in-class investigational drug, Pidnarulex(
CX-5461), in combination with BeOne Medicines’ marketed PD-1 inhibitor, tislelizumab,
across multiple advanced or metastatic solid tumors, including pancreatic cancer,
colorectal cancer, and melanoma—areas with significant unmet medical needs. The 
global multi-center design is expected to accelerate clinical validation while enhancing
the asset’s visibility, supporting future out-licensing and commercialization opportunities.

The Company aims to leverage combination therapy approaches to enter the rapidly
expanding immuno-oncology market and build sustainable long-term growth momentum.

CX-5461 features a differentiated dual mechanism of action. In addition to inhibiting
ribosomal RNA synthesis and suppressing tumor cell proliferation, it stabilizes 
G-quadruplex structures, inducing DNA damage and activating the cGAS–STING pathway.
This unique mechanism not only confers direct anti-tumor activity but also enhances
tumor immunogenicity, creating strong synergy with immune checkpoint inhibitors.
Preclinical and translational studies have demonstrated that CX-5461 can effectively
remodel the tumor microenvironment, increase tumor-infiltrating lymphocytes (TILs),
and upregulate PD-L1 expression. These findings suggest its potential to overcome
resistance and improve response rates in patients with limited benefit from current
immunotherapies, positioning CX-5461 as a promising backbone agent in combination
immunotherapy strategies.

According to market research analyses, the global cancer immunotherapy market exceeded
US$150 billion in 2025 and is projected to grow at a double-digit compound annual
growth rate, potentially surpassing US$300 billion by 2035. Within this expanding
landscape, combination therapies have emerged as a central focus for the pharmaceutical
industry, serving as a key driver for lifecycle extension and next-generation revenue
growth.

At the same time, the pharmaceutical sector is facing increasing pressure from patent
expirations of blockbuster drugs, driving strong demand for innovative assets with
differentiated mechanisms and clinical potential. Strategic licensing and M&A activities
have become primary pathways for large pharmaceutical companies to secure high-value
pipeline assets, intensifying competition for early-stage opportunities.

Against this backdrop, the current clinical trial is expected to serve as a critical
validation point for CX-5461. Pending positive efficacy and safety outcomes, the
asset has the potential to attract strong interest from global pharmaceutical companies
for licensing or acquisition, significantly enhancing its commercial prospects and
overall market value.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Senhwa Biosciences Launches Global Study, Targeting Breakthrough in Hard-to-Treat Cancers with CX-5461 and Tislelizumab Combination ](http://www.prnasia.com/story/archive/4951272_HK51272_0?rand=184833)